Prophylaxis with G-CSF in cycle 1 ranged from 1.8% (lung cancer) to 80.5% (breast cancer) among HR patients, 14.8% (lung cancer) to 55.0% (NHL) among IR + 1 patients, and 2.7% (colorectal cancer) to 20.2% (breast cancer) among all others. This evidence concerns the gene CSF3 and lung cancer.